Validation of the Non-Motor Symptoms Scale for Parkinson's Disease of Persian Version.

IF 2.1 4区医学 Q3 CLINICAL NEUROLOGY

Parkinson's Disease Pub Date : 2023-01-01 DOI:10.1155/2023/1972034

Zahra Eghlidos, Aida Abolhassanbeigi, Zahra Rahimian, Samaneh Khazraei, Vahid Reza Ostovan

{"title":"Validation of the Non-Motor Symptoms Scale for Parkinson's Disease of Persian Version.","authors":"Zahra Eghlidos, Aida Abolhassanbeigi, Zahra Rahimian, Samaneh Khazraei, Vahid Reza Ostovan","doi":"10.1155/2023/1972034","DOIUrl":null,"url":null,"abstract":"Objective: We aimed to assess the validity and reliability of the Persian version of the NonMotor Symptoms Scale (NMSS) in Iranian patients with PD.Methods: This cross-sectional study was conducted in patients with PD. After the cross-cultural adaptation of the NMSS, the acceptability, reliability, precision, and validity of the Persian NMSS were evaluated. For this purpose, in addition to NMSS, we used the following measures: Scales for Outcomes in Parkinson's Disease (SCOPA)-Autonomic (SCOPA-AUT), SCOPA-Sleep, Beck's Depression Inventory (BDI) questionnaire, Parkinson's Disease Questionnaire-8 questions (PDQ-8), SCOPA-Motor, SCOPA-Psychiatric Complications (SCOPA-PC), SCOPA-Cognition (SCOPA-COG), Mini-Mental State Examination (MMSE), Hoehn and Yahr Staging (H and Y), and Unified Parkinson Disease Rating Scale (UPDRS).Results: 186 patients were enrolled (mean age 64.46 ± 9.9 years; disease duration 5.59 ± 3.99 years; 118 (63.4%) male; mean NMSS score 52.01 ± 38.54). Neither the floor effect (2.7%) nor the ceiling effect (0.5%) was seen in NMSS total score. Cronbach's alpha of total NMSS was 0.84. The test-retest reliability was 0.93 for the NMSS total and 0.81-0.96 for domains. The standard error of measurement (SEM) was lower than half of the standard deviation for NMSS total and all domains. NMSS total showed a high correlation with UPDRS I (rs = 0.84), UPDRS II (rs = 0.58), PDQ-8 (rs = 0.61), BDI (rs = 0.71), SCOPA-sleep (rs = 0.60), and SCOPA AUT (rs = 0.66). NMSS has an acceptable discriminative validity based on disease duration and severity of disease according to H and Y staging.Conclusion: The Persian NMSS is a valid and reliable measure for evaluating the burden of nonmotor symptoms in Iranian patients with PD.","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2023 ","pages":"1972034"},"PeriodicalIF":2.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275686/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Parkinson's Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/1972034","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Objective: We aimed to assess the validity and reliability of the Persian version of the NonMotor Symptoms Scale (NMSS) in Iranian patients with PD.

Methods: This cross-sectional study was conducted in patients with PD. After the cross-cultural adaptation of the NMSS, the acceptability, reliability, precision, and validity of the Persian NMSS were evaluated. For this purpose, in addition to NMSS, we used the following measures: Scales for Outcomes in Parkinson's Disease (SCOPA)-Autonomic (SCOPA-AUT), SCOPA-Sleep, Beck's Depression Inventory (BDI) questionnaire, Parkinson's Disease Questionnaire-8 questions (PDQ-8), SCOPA-Motor, SCOPA-Psychiatric Complications (SCOPA-PC), SCOPA-Cognition (SCOPA-COG), Mini-Mental State Examination (MMSE), Hoehn and Yahr Staging (H and Y), and Unified Parkinson Disease Rating Scale (UPDRS).

Results: 186 patients were enrolled (mean age 64.46 ± 9.9 years; disease duration 5.59 ± 3.99 years; 118 (63.4%) male; mean NMSS score 52.01 ± 38.54). Neither the floor effect (2.7%) nor the ceiling effect (0.5%) was seen in NMSS total score. Cronbach's alpha of total NMSS was 0.84. The test-retest reliability was 0.93 for the NMSS total and 0.81-0.96 for domains. The standard error of measurement (SEM) was lower than half of the standard deviation for NMSS total and all domains. NMSS total showed a high correlation with UPDRS I (r_s = 0.84), UPDRS II (r_s = 0.58), PDQ-8 (r_s = 0.61), BDI (r_s = 0.71), SCOPA-sleep (r_s = 0.60), and SCOPA AUT (r_s = 0.66). NMSS has an acceptable discriminative validity based on disease duration and severity of disease according to H and Y staging.

Conclusion: The Persian NMSS is a valid and reliable measure for evaluating the burden of nonmotor symptoms in Iranian patients with PD.

查看原文本刊更多论文

波斯版帕金森病非运动症状量表的验证。

目的:我们旨在评估波斯语版非运动症状量表(NMSS)在伊朗PD患者中的效度和可靠性。方法:对PD患者进行横断面研究。经跨文化调整后，对波斯语的可接受性、信度、精确度和效度进行了评估。为此，除NMSS外，我们还使用了以下测量方法:帕金森病结局量表(SCOPA)-自主神经量表(SCOPA- aut)、SCOPA-睡眠量表、贝克抑郁量表(BDI)、帕金森病问卷-8题(PDQ-8)、SCOPA-运动量表、SCOPA-精神并发症量表(SCOPA- pc)、SCOPA-认知量表(SCOPA- cog)、简易精神状态检查量表(MMSE)、Hoehn和Yahr分期(H和Y)和统一帕金森病评定量表(UPDRS)。结果:纳入186例患者(平均年龄64.46±9.9岁;病程5.59±3.99年;男性118例(63.4%);平均NMSS评分52.01±38.54)。NMSS总分不存在最低效应(2.7%)和最高效应(0.5%)。总NMSS的Cronbach's alpha为0.84。NMSS总体的重测信度为0.93，域的重测信度为0.81 ~ 0.96。NMSS总域和各域的测量标准误差(SEM)均小于标准差的一半。NMSS总分与UPDRS I (rs = 0.84)、UPDRS II (rs = 0.58)、PDQ-8 (rs = 0.61)、BDI (rs = 0.71)、SCOPA-sleep (rs = 0.60)、SCOPA AUT (rs = 0.66)呈正相关。根据H和Y分期，NMSS在疾病持续时间和疾病严重程度上具有可接受的判别效度。结论:波斯NMSS是评估伊朗PD患者非运动症状负担的有效和可靠的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Parkinson's Disease CLINICAL NEUROLOGY-

CiteScore

5.80

自引率

3.10%

发文量

审稿时长

18 weeks

期刊介绍： Parkinson’s Disease is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to the epidemiology, etiology, pathogenesis, genetics, cellular, molecular and neurophysiology, as well as the diagnosis and treatment of Parkinson’s disease.